Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

Chemical biology & drug design - 1 Feb 2013

Xie Huan-Zhang, Lan Hai, Pan You-Li, Zou Jun, Wang Ze-Rong, Li Lin-Li, Huang Qi, Zhang Hui, Yang Sheng-Yong

Abstract excerpt

In this investigation, a common feature pharmacophore model of anaplastic lymphoma kinase inhibitors was developed based on several known anaplastic lymphoma kinase inhibitors that were co-crystallized with anaplastic lymphoma kinase. The established pharmacophore model Hypo1 was carefully validated and then adopted to screen two in silico chemical databases, Specs (202 408 compounds) and Enamine (1 105 894...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Ligands

Share to Molecular Docking Simulation

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 23107363
DOI: 10.1111/cbdd.12084

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.PMID 23107363Read ↗

Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent reviewSemantic proximity Read ↗

Anaplastic lymphoma kinase: Role in cancer and therapy perspective.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and NeuroblastomaSemantic proximity Read ↗

The Landscape of Atypical and Eukaryotic Protein Kinases.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many FacesSemantic proximity Read ↗

An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.Semantic proximity Read ↗

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.Semantic proximity Read ↗

A structural atlas of kinases inhibited by clinically approved drugs.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.Semantic proximity Read ↗

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceSemantic proximity Read ↗

Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase.Semantic proximity Read ↗

Virtual Screening and Discovery of Novel Aurora Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.